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CLUSIONS: Classical test theory-based psychometric methods
generally supported the CES-D scale as an outcome measure of
depression after stroke. DIF on some items suggests that symp-
toms experienced in post-stroke depression may differ from
depression in the general population.
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Clinical trials often employ self-rated and interviewer-rated
instruments to assess the effectiveness of anxiolytic treatments.
Understanding potential differences in these scales and their psy-
chometric properties therefore is important for interpreting trial
results. OBJECTIVES: Identify and critique key methods used to
compare psychometric properties of self-versus interviewer-rated
instruments in clinical trials for patients with anxiety disorders.
METHODS: A literature review focusing on anxiety outcome
assessments used in clinical trials was conducted in Medline,
OLGA, and PsychINFO databases of articles published before
September 2003. This study included only articles that were pub-
lished in English and reported data from clinical trials with anx-
iolytic drugs. RESULTS: From the literature review, two
commonly used instruments included the self-rated Symptom
Checklist-90, and the interviewer-rated Hamilton Rating Scale
for Anxiety. Five methodological approaches were identiﬁed: 1)
precision of measurement: means and variances of instrument
scores; 2) construct validity: comparison of underlying con-
structs for each instrument using factor analysis; 3) internal 
consistency: homogeneity of items within the same domain of an
instrument; 4) instrument sensitivity: ability of the instrument to
detect treatment effect by differentiating control from treatment
groups or between groups of different disease states; and 5)
instrument responsiveness: ability of each instrument to detect
minimal clinically important changes within patients over time
(pre-and post-treatment phases) using distribution-based and
anchor-based approaches. Tests for statistical and clinical signif-
icances in score changes are discussed. For each of the ﬁve
approaches, suggested statistical methods and examples from the
literature are presented. CONCLUSIONS: The structured tax-
onomy developed in this study will help interpret clinical trial
results that use self-rated and interviewer-rated instruments, as
well as elucidate potential methods for developing and validat-
ing new instruments to assess the effectiveness of anxiolytic treat-
ments in trials.
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OBJECTIVES: Bipolar disorder, as well as some of the pharma-
cological agents used to treat it, often impairs patients’ ability to
function on a day-to-day basis. The goal of the present study was
to develop a sensitive, psychometrically sound self-report instru-
ment that would help to identify treatments effective in maxi-
mizing the functional status of bipolar patients. METHODS:
Through consultation with key opinion leaders, literature review,
and individual in-depth interviews with bipolar patients, the
team developed a questionnaire using 50 items to address the
following domains: cognitive functioning, sleep, role function-
ing, emotional functioning, energy/vitality, social functioning,
personal management, and sexual functioning. The draft ques-
tionnaire was then tested and revised through 2 iterative sets of
cognitive interviews with 19 additional patients in multiple loca-
tions. RESULTS: In general, the pretest participants deemed the
set of constructs addressed in the questionnaire to be both com-
prehensive and representative of their daily functioning. They
also reported that the ﬁnal set of items was easy to comprehend
and to ﬁll in, noting that the 7-point Likert-type response scale
seemed optimal; the points on the scale appeared to represent
the full spectrum of answer choices, yet participants could easily
distinguish between the options. Cognitive testing also resulted
in the elimination of 17 items, which were either deemed inessen-
tial to the measurement of functional status, applicable only to
a subset of patients (eg, family responsibilities), or too similar in
content to other items. CONCLUSIONS: The resulting ques-
tionnaire addresses all constructs considered central to the func-
tional status of patients with bipolar disorder, with 33 items that
are phrased to facilitate patient comprehension and completion.
A multisite, 600-patient validation study is currently under way
to evaluate the psychometric properties of this instrument.
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OBJECTIVES: The potential for antipsychotic-induced diabetes
is an important issue. Retrospective studies using large patient
databases have had conﬂicting ﬁndings regarding diabetes risks
associated with different antipsychotics. METHODS: Claims
data for thousands of psychosis patients treated or untreated
with antipsychotics were analyzed. Screening for preexisting dia-
betes, identiﬁcation of diabetes with prescription claims only,
and requirement of antipsychotic monotherapy provide better
control for confounding inﬂuences and represent a stronger
study design. Diabetes odds ratios for risperidone, olanzapine,
quetiapine, or conventional antipsychotics versus non-treatment
were estimated for all patients and for patients stratiﬁed by dose
levels. Logistic regression controlled for age, sex, type of 
psychosis, length of observation/treatment, preexisting excess
weight, and use of other drugs with diabetogenic effects.
RESULTS: Under a weaker study design, all of the antipsychotics
were associated with signiﬁcantly higher odds of diabetes rela-
tive to non-treatment. Odds ratios (95% conﬁdence intervals
[CI]) were: risperidone 1.388 (1.276–1.509), olanzapine 1.331
(1.224–1.446), quetiapine 1.394 (1.247–1.559), and conven-
tional antipsychotics 1.365 (1.238–1.503). Under a stronger
study design, relative odds for risperidone and quetiapine
declined, becoming statistically insigniﬁcant, whereas odds for
olanzapine and conventional antipsychotics increased. Odds
ratios (95% CI) were: risperidone 1.224 (0.962–1.562), olanza-
pine 1.858 (1.549–2.238), quetiapine 1.087 (0.742–1.612), and
conventional antipsychotics 1.755 (1.381–2.221). With quetiap-
ine, odds of diabetes were not signiﬁcantly increased at any dose
level relative to non-treatment. Odds were signiﬁcantly increased
